Finance

Lists
Why is IKT up 3,14%?
Dive Deeper
IKT:NASDAQ
Inhibikase Therapeutics Inc
1,97 $
+3,14%
(+0,060) 1D
1,97 $
0,00% (0,00)
After hours
Closed: 9 қаз., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IKT...
Open
1,90 $
High
1,98 $
Low
1,87 $
Mkt. cap
274,89 млн
Avg. vol.
518,16 м.
Volume
435,03 м.
52-wk high
2,61 $
52-wk low
1,33 $
EPS
-0,44 $
Beta
0,89
Shares outstanding
139,54 млн
No. of employees
35
Open
1,90 $
High
1,98 $
Low
1,87 $
Mkt. cap
274,89 млн
Avg. vol.
518,16 м.
Volume
435,03 м.
52-wk high
2,61 $
52-wk low
1,33 $
EPS
-0,44 $
Beta
0,89
Shares outstanding
139,54 млн
No. of employees
35
News stories
From web sources and news partners
About Inhibikase Therapeutics Inc
CEO-
Employees35
Founded2008
HeadquartersWilmington, Делавэр, Америка Құрама Штаттары
Sector-
Websiteinhibikase.com
Analyst ratings
Based on 5 analysts giving stock ratings to IKT in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for IKT in the last 3 months.
Highest
Current 1,97 $
8,00 $ (+306,09%)
Average
6,40 $ (+224,87%)
Lowest
5,00 $ (+153,81%)
Analyst
Recommendation
Action
Price target
Projected
Date
Gaurav Maini
LifeSci Capital
Buy
Maintained
5,00 $
+153,8%
09/15/2026
Jason McCarthy
Maxim Group
Buy
Maintained
8,00 $
+306,1%
08/13/2026
Mazahir Alimohamed
Oppenheimer
Buy
Maintained
5,00 $
+153,8%
08/12/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
8,00 $
+306,1%
07/31/2026
Jason Zemansky
Bank of America Securities
Buy
Maintained
6,00 $
+204,6%
07/27/2026
Olivia Brayer
Cantor Fitzgerald
Buy
Maintained
4,00 $
+103%
05/18/2026
Aydin Huseynov
Ladenburg Thalmann & Co.
Buy
Initiated
4,00 $
+103%
03/04/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
-
-
-
-
Cost of goods sold
7,65 млн
-23,43 млн
-
-
Cost of revenue
7,65 млн
-23,43 млн
-
-
Research and development expenses
-
22,39 млн
10,84 млн
13,39 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,61 млн
6,77 млн
7,38 млн
7,66 млн
Operating expense
5,61 млн
29,17 млн
18,22 млн
21,05 млн
Total operating expenses
13,26 млн
5,73 млн
18,22 млн
21,05 млн
Operating income
-13,26 млн
-5,73 млн
-18,22 млн
-21,05 млн
Other non operating income
-
-
1,46 млн
1,46 млн
EBT including unusual items
-11,93 млн
-12,73 млн
-16,38 млн
-19,59 млн
EBT excluding unusual items
-12,42 млн
-4,69 млн
-16,75 млн
-19,59 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-11,93 млн
-12,73 млн
-16,38 млн
-19,59 млн
Net profit margin
-
-
-
-
Earnings per share
-
-
-0,10
-0,11
Interest and investment income
838,09 м.
1,04 млн
-
-
Interest expense
-
-
-
-
Net interest expenses
838,09 м.
1,04 млн
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-13,24 млн
-5,73 млн
-18,20 млн
-21,04 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google қолданбалары